We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-0.47%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52M
AUM Growth
-$6.16B
Cap. Flow
-$249M
Cap. Flow %
-4,517.93%
Top 10 Hldgs %
32.16%
Holding
158
New
15
Increased
26
Reduced
36
Closed
15

Top Buys

Rank Stock Value
1
PGNY icon
Progyny
PGNY
+$22.4M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$19.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$19.4M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$17.1M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$76.7M
2
PFE icon
Pfizer
PFE
+$59.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$50.3M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$40.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMIC
126
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$2.06K 0.04%
18,023
-58,670
-76% -$6.88M
PHGE icon
127
BiomX
PHGE
$1.96M
$2.05K 0.04%
14,808
– –
GH icon
128
CALL
Guardant Health
GH
$19.1B
$2.02K 0.04%
+50,000
New +$2.48M
KALV
129
DELISTED
KalVista Pharmaceuticals
KALV
$1.82K 0.03%
+185,400
New +$2.05M
SGHT icon
130
Sight Sciences
SGHT
$290M
$1.8K 0.03%
200,000
– –
EYPT icon
131
EyePoint Inc
EYPT
$991M
$1.69K 0.03%
+214,100
New +$2.15M
SRPT icon
132
Sarepta Therapeutics
SRPT
$1.62B
$1.5K 0.03%
20,000
-19,100
-49% -$1.41M
XFOR icon
133
X4 Pharmaceuticals
XFOR
$376M
$1.33K 0.02%
45,795
– –
SONX
134
DELISTED
Sonendo, Inc.
SONX
$1.24K 0.02%
723,478
-1,244,702
-63% -$3.32M
TRML
135
DELISTED
Tourmaline Bio
TRML
$1.06K 0.02%
23,600
-1,124
-5% -$88.7K
VIGL
136
DELISTED
Vigil Neuroscience
VIGL
$1.06K 0.02%
411,191
– –
SYRE icon
137
Spyre Therapeutics
SYRE
$8.31B
$908 0.02%
71,889
-46,356
-39% -$1.62M
LBPH
138
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$351 0.01%
113,500
– –
APTX
139
DELISTED
Aptinyx Inc. Common Stock
APTX
$300 0.01%
538,500
– –
CABA icon
140
Cabaletta Bio
CABA
$440M
– –
-577,509
Closed -$1.17M
DXCM icon
141
DexCom
DXCM
$29.3B
– –
-599,600
Closed -$76.7M
LKFT
142
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-208,225
Closed -$12.9M
ILMN icon
143
Illumina
ILMN
$29.3B
– –
-46,363
Closed -$15.8M
NBP
144
NovaBridge Biosciences American Depositary Shares
NBP
$193M
– –
-111,120
Closed -$1.8M
PYXS icon
145
Pyxis Oncology
PYXS
$192M
– –
-143,640
Closed -$580K
RARE icon
146
Ultragenyx Pharmaceutical
RARE
$2.52B
– –
-227,600
Closed -$16.5M
EXAI
147
DELISTED
Exscientia Plc American Depositary Shares
EXAI
– –
-125,000
Closed -$1.8M
ASLN
148
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-48,530
Closed -$1.75M
NSTG
149
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-1,157,387
Closed -$40.2M
REUN
150
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
– –
-115,386
Closed -$762K
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2022 Portfolio in Review

As of Q2 2022, OrbiMed held 158 positions worth $5.52M, down 100% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $249M in Q2 2022, closing 15 positions and reducing 36 holdings. Its most notable exit was DexCom, an estimated $76.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

Against the trend, OrbiMed opened a new position in Progyny worth $18.2K.

  • OrbiMed's largest Q2 2022 buy was Progyny: 625,000 shares worth $18.2K.
  • OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
  • OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
  • OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
  • OrbiMed's ten largest holdings make up 32% of its $5.52M portfolio in Q2 2022.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2022.
  • OrbiMed's portfolio value fell 100% quarter-over-quarter to $5.52M.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.